Skip to search formSkip to main contentSkip to account menu

Tevagrastim

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
The comparison of effectiveness and safety between different biosimilars of G‐CSF in the mobilization of peripheral blood stem cells (PBSCs) for autologous transplantation (autologous peripheral…
Autologous peripheral blood marrow stem cell transplantation (auto‐PBSCT) preceded by high‐dose chemotherapy is a well‐known… 
2016
2016
Real-World Safety Experience for Short-Acting Recombinant Human Granulocyte Colony-Stimulating Factor
Introduction: Marketed therapeutic products are subject to periodic benefit-risk evaluation reports (PBRERs), which provide… 
Review
2016
Review
2016
Tbo-Filgrastim: A Review in Neutropenic Conditions
Tbo-filgrastim (filgrastim XM02; Biograstim®, Ratiograstim®, Tevagrastim®) is approved in the EU as a biosimilar of filgrastim… 
2015
2015
Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute…
BACKGROUND Filgrastim biosimilars have recently been introduced into clinical practice. To date biosimilars have demonstrated… 
2013
2013
The Use of Tevagrastim (Biosimilar Filgrastim XMO2) for Hematopoietic Stem Cell Mobilization in HLA Matched Sibling Donors for Allogeneic Stem Cell Transplantation to AML/MDS Patients
2013
2013
TCH-012 Differences in Purity Between Biosimilar Filgrastims and Copy Biological Filgrastims
Background Biosimilars are follow-on versions of peptide biological drugs, and differences in manufacturing and formulation can… 
2012
2012
New expression method and characterization of recombinant human granulocyte colony stimulating factor in a stable protein formulation.
Human recombinant granulocyte colony stimulating factor (rhG-CSF) is widely used in hematology and oncology for the treatment of… 
Review
2011
Review
2011
The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
The Biologics Price Competition and Innovation Act of 2009 ("Biosimilars Act") is for the field of pharmaceutical products the… 
2011
2011
Presently available biosimilars in hematology-oncology — Part II: G-CSF
RésuméLes produits biopharmaceutiques étaient des copies de protéines humaines endogènes développées au milieu des années 1990 et… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)